



One

Olympus is making strides toward a new growth stage.
Uniting the desires of everyone at the Olympus Group,
I will lead us to achieving robust growth.

Four years have passed since I took up the mantle of president in 2012. The current management team, of which I am a part, was appointed to create a new Olympus in the wake of the series of scandals. As such, regaining trust and improving corporate value have been our top priorities. Devoted to once again realizing a strong Olympus, we proceeded to restructure corporate governance systems and achieve substantial improvements in our financial health, which was in a state of crisis after the scandals. These efforts led to incredibly impressive performance in our mainstay Medical Business, and the Company was thereby able to achieve record-breaking net income in fiscal 2016. Previously, we had faced various causes for uncertainty, including issues related to negotiations with the U.S. Department of Justice. However, we steadily resolved such issues, and we are now able to secure a certain amount of funds, enabling us to resume dividend payments. I therefore feel confident saying that we were generally able to achieve the goals of the plan over the past four years. Furthermore, a new matrix style of business operation was adopted in April 2015. This system has begun functioning exceptionally well, as indicated by an increase in cross-business and cross-region discussion and enhanced global coordination.

With fiscal 2017, we kicked off our new medium-term management plan 2016 Corporate Strategic Plan, or 16CSP for short. Forged during the course of plentiful discussions among the management team, this plan was announced at OLYMPUS IR DAY 2016, which, taking place in Tokyo in March 2016, was our first time to hold such an event. Following this announcement, Chief Financial Officer Yasuo Takeuchi and I visited several institutional investors around the world, explaining to them in detail our directives, policies, and growth strategies. The response to this plan has been overwhelmingly positive, for which I am most grateful. Such high expectations for our future make palpable the fact that Olympus is now making powerful strides forward.

Having moved passed the stage of reconstructing management, 16CSP will serve as an important strategy for guiding us in realizing sustainable growth and development in the next growth stage. We have set a course to this new stage, the next destination on our journey toward being a strong global player in the medical field. Moreover, we will celebrate the 100th anniversary of the Company's founding in 2019, three years from now. We thus seek to strengthen the foundations for our growth over the next 100 years through 16CSP while also striving to improve corporate value by developing an aggressive business portfolio. Olympus stands out among its peers as one of the few companies worldwide from which organic growth can be expected. Priding ourselves on this distinction, we will boldly tackle new challenges with the aim of transforming Olympus into a truly global company. We are firmly committed to living up to your expectations, and I assure you that this commitment will drive me as I lead the Company. I hope you will look forward to the future of Olympus with great anticipation.

August 2016

Hiroyuki Sasa

President and Representative Director



Olympus